NAYA Therapeutics is a clinical‑stage biopharmaceutical company developing astatine‑211‑based radiopharmaceuticals and NK‑cell‑engaging bifunctional antibodies to treat advanced hepatocellular carcinoma and multiple myeloma. Its therapies aim to deliver high‑energy alpha particles or activate natural killer cells for deeper, more durable responses in patients who have failed standard‑of‑care treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with advanced hepatocellular carcinoma (HCC) and multiple myeloma often do not respond to existing standard-of-care therapies, leading to limited survival and few durable treatment options. Additionally, the development of effective radiopharmaceuticals is constrained by supply chain challenges and safety concerns associated with current alpha‑emitters.
Solution
NAYA Therapeutics is a clinical‑stage biopharmaceutical company developing two complementary modalities to address unmet oncology needs. It creates astatine‑211‑based radiopharmaceuticals, leveraging the isotope’s favorable safety profile and on‑demand supply to deliver high‑energy alpha particles to tumor cells. In parallel, the company engineers NK‑cell‑engaging bifunctional antibodies that simultaneously bind tumor antigens and activate natural killer cells via NKp46 and CD16, aiming to overcome resistance to PD‑(L)1 and VEGF inhibitors. The pipeline includes NY‑700, a GPC3‑targeted astatine‑211 therapy for HCC, and NY‑303/NY‑338 bispecific antibodies for HCC and multiple myeloma respectively, each designed to provide deeper, more durable responses in patients who have failed existing treatments.
Target Audience
Primary customers are oncology clinicians and pharmaceutical partners seeking novel therapies for patients with advanced HCC and multiple myeloma who have progressed on standard treatments.
Features
- Astatine‑211 alpha‑emitting radiopharmaceuticals with outpatient‑compatible safety and supply advantages over actinium‑225
- GPC3‑targeted delivery for hepatocellular carcinoma, enabling precise tumor localization
- NK‑cell‑engaging bifunctional antibodies that bind tumor antigens and activate NKp46/CD16 pathways
- Dual targeting formats (e.g., CD38/NKp46/CD16) to address limitations of existing monoclonal antibodies and BCMA T‑cell engagers
- Designed for combination with checkpoint inhibitors or VEGF blockers to broaden therapeutic impact
- Clinical development plans include Phase I/IIa trials slated for 2025‑2026, with clear regulatory pathways